Recent studies reported that intranasal insulin administration for the treatment of CNS disorders including mild cognitive impairment and AD (ClinicalTrials.gov Identifier: NCT01767909, Craft et al., 2020). The gene discussed is INS; the disease is central nervous system disorder.